Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Int J Psychoanal ; 104(5): 936-940, 2023 10.
Article in English | MEDLINE | ID: mdl-37902486

ABSTRACT

The three-level model (3-LM) tracks transformation in psychoanalytic cases via a focused working group study of detailed clinical material. This Panel was a continuation of a series of programmes on the work of the Clinical Observation Committee held at previous IPA Congresses in Mexico City, Prague, Boston, Buenos Aires, London, and in an Online Congress during the pandemic. In this presentation, panellists summarized how the 3-LM worked, with two summarizing cases presented using this method at their Institute.


Subject(s)
Pandemics , Psychoanalysis , Humans , London
2.
Am J Gastroenterol ; 106(10): 1777-86, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21769136

ABSTRACT

OBJECTIVES: Mental health and substance abuse (MH/SA) comorbidities are the most oft-cited reasons for deferral from peginterferon (PegIFN) therapy for chronic hepatitis C virus (HCV). We sought to determine whether an integrated care intervention (INT) for patients deferred from PegIFN owing to MH/SA could improve subsequent treatment eligibility rates. METHODS: In this randomized controlled trial, 101 HCV patients who were evaluated at two hepatology centers and deferred from antiviral therapy owing to MH/SA were enrolled. Participants were randomized to an INT (N=50) or standard of care (SC; N=51). The INT group received counseling and case management for up to 9 months. All participants underwent 3-, 6-, and 9-month clinical follow-up visits, where hepatologists, masked to group, re-evaluated patients for treatment eligibility. Standardized mood and alcohol use instruments were administered to all participants to aid clinicians in treatment decisions. RESULTS: Of 101 participants, the mean age was 48 years and 50% were men, 61% Caucasian, and 77% genotype 1. Patients were initially deferred owing to psychiatric issues (35%), alcohol abuse (31%), drug abuse (9%), or more than one of these reasons (26%). In an intent-to-treat analysis, 42% (21/50) of INT participants became eligible for therapy compared to 18% (9/51) of SC participants (P=0.009, relative risk (RR)=2.38, 95% confidence interval (CI) (1.21, 4.68)). When baseline predictors significant at P<0.10 in univariate models were entered into multivariate models adjusted for treatment group, only baseline depression remained significant (P=0.05, RR=0.98, 95% CI (0.96, 1.00)). With the exception of a model adjusted for genotype, treatment group remained significant in all models. CONCLUSIONS: This trial suggests that INTs can increase eligibility for HCV treatment and expand treatment to the underserved population with MH/SA comorbidities.


Subject(s)
Antiviral Agents/administration & dosage , Delivery of Health Care, Integrated/statistics & numerical data , Eligibility Determination/standards , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Mental Disorders/epidemiology , Polyethylene Glycols/administration & dosage , Substance-Related Disorders/epidemiology , Adult , Comorbidity , Female , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Recombinant Proteins/administration & dosage , Surveys and Questionnaires , United States/epidemiology
4.
Dig Dis Sci ; 52(11): 3251-8, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17394072

ABSTRACT

Many patients are excluded from HCV treatment due to psychiatric issues (PI) and substance abuse (SA). We sought to determine deferral rates and reasons for nontreatment, determine whether patients initially deferred for PI or SA subsequently received antiviral therapy, and compare treatment outcomes of these patients with patients who were not deferred. A retrospective analysis of 433 patients with HCV was conducted. Seventy-five percent of patients were deferred from treatment. Primary deferral reasons were PI (34.3%) and SA (33.6%). Characteristics were similar between eligible and ineligible treatment candidates. Of those initially deferred from therapy, over half returned for follow-up; however, only 13% eventually received treatment. Patients initially deferred for PI/SA but subsequently treated were less likely to complete treatment than patients without these comorbidities (48% vs. 13%). SVR was lower in patients with PI/SA compared to those without (26% vs. 47%). Deferral rates for PI/SA remain high, and these patients are rarely treated at subsequent clinic visits. When patients are deferred for PI/SA but later treated, they have significantly higher rates of not completing treatment and a trend toward lower SVR rates.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Interferons/therapeutic use , Mental Disorders/complications , Substance-Related Disorders/complications , Treatment Refusal/statistics & numerical data , Female , Follow-Up Studies , Hepatitis C/complications , Hepatitis C/psychology , Humans , Male , Mental Disorders/psychology , Middle Aged , Retrospective Studies , Substance-Related Disorders/psychology , Treatment Outcome , Treatment Refusal/psychology
5.
J Clin Gastroenterol ; 40(3): 220-4, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16633123

ABSTRACT

GOAL: Our aim was to assess stigmatization by evaluating the impact of hepatitis C virus (HCV) on social interactions, feelings of rejection, internalized shame, and financial insecurity, and behavior. BACKGROUND: HCV patients suffer from slowly progressive disease. Although much research has improved the long-term prognosis of chronic HCV, quality of life may be affected by perceived social stigmatization. STUDY: In a cross-sectional study, HCV patients without cirrhosis or significant comorbidities were recruited from the University of North Carolina viral hepatitis clinic. Subjects completed a questionnaire administered by a trained interviewer that assessed changes in sexual behavior, personal hygiene habits, social function, and interactions. Additionally, subjects completed validated, standardized questionnaires, the Health Status Questionnaire, and the SCL-90-R. Frequencies were calculated for the prevalence of stigmatization and altered social interaction. Correlations between education and behavior changes were assessed. A series of multivariate analyses controlling for age, sex, and education were performed to assess the association between HCV acquisition risk and stigmatization. RESULTS: One hundred seventy-five of 217 potential subjects (81%) participated in the survey. The average age was 45.2+/-7.7 years. Fifty-five percent were men and 53% were single. Twenty-nine percent had some college education. Risk factors for HCV acquisition included transfusion (21%) and injection drug use (29%), whereas 32% had an unknown mode of infection. Among common activities, 47% were less likely to share drinking glasses, 14% were less likely to prepare food, and one-third of subjects were less likely to share a towel. Thirty-five percent of respondents reported changes in their sexual practices. Decreased frequency of kissing and sexual intercourse was reported in 20% and 27% of individuals, respectively. Almost half of the single subjects reported increased use of condoms compared with only 20% among married couples. The majority of subjects perceived financial insecurity, internalized shame, and social rejection. Only 39% reported health impairment. Education level did not influence behavior change. CONCLUSION: The majority of HCV subjects alter common behaviors and report financial insecurity, internalized shame, and social rejection, regardless of the method of HCV acquisition or socioeconomic status. These findings indicate that all HCV individuals be counseled and encouraged to participate in educational programs at the time of diagnosis to reduce unnecessary behavioral changes and stigmatization perceptions to improve quality of life.


Subject(s)
Hepatitis C, Chronic/psychology , Prejudice , Quality of Life/psychology , Cross-Sectional Studies , Female , Humans , Interpersonal Relations , Male , Middle Aged , Sickness Impact Profile , Surveys and Questionnaires
7.
N C Med J ; 65(1): 12-5, 2004.
Article in English | MEDLINE | ID: mdl-15052704

ABSTRACT

OBJECTIVE: National and state data document racial differences in colorectal cancer (CRC) mortality and incidence. Screening for CRC reduces cancer incidence and deaths. Racial differences in colorectal cancer screening behavior may contribute to the racial disparity in incidence and mortality. The purpose of this study was to determine if colorectal cancer screening rates are different between blacks and whites while controlling for potential confounders. STUDY DESIGN: Cross-sectional survey. DATA SOURCE(S)/STUDY SETTING: We used data from the North Carolina Colon Cancer Study, a population-based case-control study conducted in 33 counties of North Carolina. We analyzed data from 598 control subjects who were eligible for colorectal cancer screening. METHODS: Trained nurses conducted face-to-face interviews from October 1996 through October 2000. RESULTS: Overall, 50% of the respondents were compliant with CRC screening guidelines. In the multivariable logistic regression model having a regular doctor and participation in a general medical exam were significantly associated with current screening status with odds ratios (OR) (95% confidence interval (CI)) of 3.8 (1.7-8.3) and 3.7 (2.1-6.7), respectively. Older age was a significant predictor of current screening status with an OR (95% CI) of 2.9 (1.7-4.8) for those 60-69 compared to respondents 50-59 and OR 3.2 (1.9-5.5) for those 70 and older compared to respondents 50-59. After adjusting for age, having a regular doctor and participation in general medical exams, race was not significantly associated with current CRC screening status, with an OR of 1.1 (95% CI 0.7-1.6). CONCLUSION: CRC screening rates in North Carolina were low. Race was not a significant determinant of screening behavior and therefore does not explain the racial disparity in incidence or survival. Older age, having a regular doctor and participating in general medical exams were significant predictors of CRC screening. RELEVANCE: This study reinforces the fact that screening rates in North Carolina are low despite the strong evidence that colorectal cancer screening reduces cancer deaths.


Subject(s)
Black People/statistics & numerical data , Colorectal Neoplasms/prevention & control , Mass Screening/statistics & numerical data , White People/statistics & numerical data , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , North Carolina/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...